Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules.
Yariswamy ManjunathKanve Nagaraj SuvileshJonathan B MitchemDiego M Avella PatinoEric T KimchiKevin F Staveley-O'CarrollKlaus PantelHuang YiGuangfu LiPeter K HarrisAadel A ChaudhuriJussuf T KaifiPublished in: JCO precision oncology (2022)
Cellular liquid biomarkers have a potential to complement LDCT interpretation of suspicious Lung-RADS 4 nodules to distinguish NSCLC from benign lung nodules. A future prospective, large-scale, multicenter clinical trial should validate the role of cellular liquid biomarkers in improving diagnostic accuracy in high-risk patients with Lung-RADS 4 nodules.